Search Results

This homogeneous tricyclics serum tox enzyme immunoassay is intended to be used for qualitative and semiquantitative determination of tricyclic antidepressants in serum, plasma or urine of patients suspected of drug overdose. A 300 ng/mL nortriptyline cutoff calibrator is used in this assay to differentiate a positive from a negative sample. Detection of the drug presence and its approximate concentration in serum, plasma or urine from patients suspected of drug overdose can assist the physician in diagnosis and determination of steps towards treatment.

homogeneous tricyclics serum tox enzyme immunoassay

This document is a 510(k) clearance letter from the FDA for a medical device called the "Tricyclic Serum Tox EIA Assay." This letter grants permission to market the device, indicating that it has been found substantially equivalent to a predicate device.

Unfortunately, the provided document {0}, {1}, and {2} does not contain the detailed information necessary to answer the questions about acceptance criteria, study design, sample sizes, expert qualifications, or ground truth establishment.

The document primarily focuses on the regulatory clearance process and states the intended use of the device. It does not include a performance study report or any data related to method validation or clinical trials that would detail acceptance criteria and a study proving the device meets them.

Therefore, I cannot provide the requested information based on the provided text. To answer these questions, a separate document detailing the device's performance study, such as a summary of safety and effectiveness, would be needed.

Ask a specific question about this device